var data={"title":"Sargramostim: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sargramostim: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6936?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sargramostim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sargramostim: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sargramostim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sargramostim: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220032\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Leukine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220033\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Leukine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220055\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220035\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May round the dose to the nearest vial size (Ozer 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (following induction chemotherapy):</b> Adults &ge;55 years: IV: 250 mcg/m<sup>2</sup>/day (infused over 4 hours) starting approximately on day 11 or 4 days following the completion of induction chemotherapy (if day 10 bone marrow is hypoplastic with &lt;5% blasts), continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days or a maximum of 42 days. If ANC &gt;20,000/mm<sup>3</sup>, interrupt treatment or reduce the dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a second cycle of chemotherapy is necessary, administer ~4 days after the completion of chemotherapy if the bone marrow is hypoplastic with &lt;5% blasts</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinue sargramostim immediately if leukemic regrowth occurs. If a severe adverse reaction occurs, reduce the dose by 50% or temporarily discontinue the dose until the reaction abates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone marrow transplantation (allogeneic or autologous) failure or engraftment delay:</b> IV: 250 mcg/m<sup>2</sup>/day (infused over 2 hours) for 14 days; If engraftment has not occurred after 7 days off sargramostim, may repeat. If engraftment still has not occurred after 7 days off sargramostim, a third course of 500 mcg/m<sup>2</sup>/day for 14 days may be attempted. If there is still no improvement, it is unlikely that further dose escalation will be of benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a severe adverse reaction occurs, reduce the dose by 50% or temporarily discontinue the dose until the reaction abates</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If blast cells appear or disease progression occurs, discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC &gt;20,000 cells/mm<sup>3</sup>, interrupt treatment or reduce the dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myeloid reconstitution after allogeneic or autologous bone marrow transplantation:</b> IV: 250 mcg/m<sup>2</sup>/day (infused over 2 hours), begin 2 to 4 hours after the marrow infusion and &ge;24 hours after chemotherapy or radiotherapy, when the post marrow infusion ANC is &lt;500/mm<sup>3</sup>, and continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days. If ANC &gt;20,000/mm<sup>3</sup>, interrupt treatment or reduce the dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a severe adverse reaction occurs, reduce dose by 50% or temporarily discontinue the dose until the reaction abates</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If blast cells appear or progression of the underlying disease occurs, discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral stem cell transplantation (autologous), mobilization:</b> IV, SubQ: 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SubQ once daily; continue the same dose throughout peripheral blood progenitor cell collection. If WBC &gt;50,000/mm<sup>3</sup>, reduce the dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The optimal schedule for peripheral blood progenitor cell collection has not been established (usually begun by day 5 and performed daily until protocol specified targets are achieved). If adequate numbers of progenitor cells are not collected, consider other mobilization therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral stem cell transplantation (autologous), post-transplant:</b> IV, SubQ: 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SubQ once daily beginning immediately following infusion of progenitor cells; continue until ANC is &gt;1,500/mm<sup>3</sup> for 3 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome, acute (off-label use):</b> SubQ: 250 mcg/m<sup>2</sup>/day; continue until ANC &gt;1,000/mm<sup>3</sup> (Waselenko 2004). ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 gray (Gy) and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary prophylaxis of neutropenia in patients receiving chemotherapy (outside transplant and AML) or who are at high risk for neutropenic fever (off-label use):</b> SubQ: 250 mcg/m<sup>2</sup>/day (may round to the nearest vial size [Ozer 2000]) beginning at least 24 hours after chemotherapy administration; continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days (Smith 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46193210\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sargramostim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sargramostim: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Do not administer lyophilized sargramostim reconstituted with bacteriostatic water for injection (0.9% benzyl alcohol) to neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome, acute (off-label use):</b> Children and Adolescents: SubQ: 250 mcg/m<sup>2</sup>/day; continue until ANC &gt;1,000/mm<sup>3</sup> (Waselenko 2004). ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 gray (Gy) and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroblastoma, high-risk (off-label use):</b> Children and Adolescents: SubQ or IV: 250 mcg/m<sup>2</sup> once daily for 14 days, beginning 3 days prior to administration of dinutuximab (each cycle is 28 days); sargramostim is administered during cycles 1, 3, and 5 (regimen also includes dinutuximab, isotretinoin, and aldesleukin) (Yu 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220036\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553572\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553573\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220011\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leukine: 250 mcg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219996\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220015\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Sargramostim is administered as a subcutaneous injection or intravenous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 2 hours, 4 hours or 24 hours (indication specific). An in-line membrane filter should <b>NOT</b> be used for intravenous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer subcutaneously into the thigh, abdomen (avoiding navel/waistline), or outer upper arm; rotate injection sites. Do not inject into areas that are tender, bruised, red, or hard. Allow to reach room temperature 30 minutes prior to injection. Administer without further dilution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220014\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML; following induction chemotherapy): </b>To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in older adults (&ge;55 years of age)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone marrow transplant (allogeneic or autologous) failure or engraftment delay:</b> For graft failure or engraftment delay in patients who have undergone allogeneic or autologous bone marrow transplantation (in the presence or absence of infection), to prolong survival (survival benefit may be greater in patients with autologous bone marrow transplant failure or engraftment delay, no previous total body irradiation, malignancy other than leukemia, or multiple organ failure score &le;2)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myeloid reconstitution after allogeneic bone marrow transplantation:</b> To accelerate myeloid recovery in patients undergoing allogeneic bone marrow transplant from HLA-matched related donors (safe and effective in accelerating myeloid engraftment, reducing the incidence of bacteremia and other culture-positive infections, and shortening the median hospitalization duration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myeloid reconstitution after autologous bone marrow transplantation:</b> To accelerate myeloid recovery following transplantation in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Hodgkin lymphoma patients undergoing autologous bone marrow transplant (safe and effective in accelerating myeloid engraftment, reducing the median duration of antibiotic administration, reducing the median duration of infectious episodes, and shortening the median hospitalization duration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral stem cell transplantation (autologous), mobilization and post-transplant:</b> Mobilization of hematopoietic progenitor cells for collection by leukapheresis (increases the number of progenitor cells capable of engraftment and may lead to more rapid engraftment); to accelerate myeloid reconstitution following peripheral blood progenitor cell transplantation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25472097\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hematopoietic radiation injury syndrome, acute; Neuroblastoma, high-risk (pediatrics); Primary prophylaxis of neutropenia in patients receiving chemotherapy (outside transplant and AML) or who are at high risk for neutropenic fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220065\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Leukine may be confused with Leukeran, leucovorin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220003\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (34%), edema (13% to 25%), pericardial effusion (4% to 25%), chest pain (15%), peripheral edema (11%), tachycardia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (57%), headache (26%), chills (25%), anxiety (11%), insomnia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (44% to 77%), pruritus (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (37%), hyperglycemia (25%), hypercholesterolemia (17%), hypomagnesemia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (81% to 89%), nausea (58% to 70%), vomiting (46% to 70%), abdominal pain (38%), anorexia (13%), hematemesis (13%), dysphagia (11%), gastrointestinal hemorrhage (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (66%), ostealgia (21%), arthralgia (11% to 21%), myalgia (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Retinal hemorrhage (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (23%), increased serum creatinine (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (23%), epistaxis (17%), dyspnea (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (81%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, capillary leak syndrome, cardiac arrhythmia, dizziness, eosinophilia, flushing, hypotension, hypoxia, injection site reaction, leukocytosis, liver function impairment (transient), pain, prolonged prothrombin time, respiratory distress, supraventricular cardiac arrhythmia, syncope, thrombocythemia, thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220018\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sargramostim, yeast-derived products, or any component of the formulation; concomitant use with cytotoxic chemotherapy and radiation therapy or within 24 hours preceding/following chemotherapy or radiation therapy; patients with excessive (&ge;10%) leukemic myeloid blasts in bone marrow or peripheral blood</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220000\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; First-dose effect: A &ldquo;first-dose effect&rdquo;, characterized by respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia, may occur (rarely) with the first dose of a cycle and resolve with appropriate symptomatic treatment; symptoms do not usually occur with subsequent doses within that cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported; fluid retention has been shown to be reversible with dosage reduction or discontinuation of sargramostim with or without concomitant use of diuretics. Use with caution in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure; may exacerbate fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: If there is a rapid increase in blood counts (ANC &gt;20,000/mm<sup>3</sup> or platelets &gt;500,000/mm<sup>3</sup>), decrease the dose by 50% or discontinue therapy. Excessive blood counts should fall to normal within 3 to 7 days after the discontinuation of therapy. Monitor CBC with differential twice weekly during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious allergic and anaphylactic reactions have been reported; discontinue immediately and initiate appropriate therapy if a serious allergic or anaphylactic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenicity: Treatment with sargramostim may induce neutralizing anti-drug antibodies. Antibody formation may be related to duration of sargramostim exposure; use sargramostim for the shortest duration necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary symptoms: Sequestration of granulocytes in pulmonary circulation and dyspnea have been reported; monitor respiratory symptoms during and following IV infusion. Decrease infusion rate by 50% if dyspnea occurs; discontinue the infusion if dyspnea persists despite reduction in the rate of administration. Subsequent doses may be administered at the standard rate with careful monitoring. Use with caution in patients with hypoxia or pre-existing pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Use with caution in patients with pre-existing cardiac disease. Reversible transient supraventricular arrhythmias have been reported, especially in patients with a history of arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; hyperbilirubinemia and elevated transaminases have been observed in this patient population. Monitor hepatic function at least every other week in patients with history of hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; serum creatinine elevations have been observed in this patient population. Monitor renal function at least every other week in patients with history of renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytotoxic chemotherapy/radiotherapy: Simultaneous administration, or administration 24 hours preceding/following cytotoxic chemotherapy or radiotherapy is contraindicated due to the sensitivity of rapidly dividing hematopoietic progenitor cells.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly patients: The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update recommend that prophylactic colony-stimulating factors be used in patients &ge;65 years with diffuse aggressive lymphoma treated with curative chemotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), especially if patients have comorbid conditions (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: CSFs should not be routinely used in the treatment of established neutropenic fever. Colony-stimulating factors may be considered in cancer patients with febrile neutropenia who are at high risk for infection-associated complications or who have prognostic factors indicative of a poor clinical outcome (eg, prolonged and severe neutropenia, age &gt;65 years, hypotension, pneumonia, sepsis syndrome, presence of invasive fungal infection, uncontrolled primary disease, hospitalization at the time of fever development) (Freifeld 2011, Smith 2006). CSFs should not be routinely used for patients with neutropenia who are afebrile. Dose-dense regimens that require CSFs should only be used within the context of a clinical trial or if supported by convincing evidence (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Efficacy: Limited response to sargramostim may be seen in patients who have received bone marrow purged by chemical agents which do not preserve an adequate number of responsive hematopoietic progenitors (eg, &lt;1.2 x 10<sup>4</sup>/kg progenitors). In patients receiving autologous bone marrow transplant, response to sargramostim may be limited if extensive radiotherapy to the abdomen or chest or multiple myelotoxic agents were administered prior to transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral blood progenitor cell mobilization: Limited in vitro data suggest that when using sargramostim to mobilize peripheral blood progenitor cells, tumor cells may be released and reinfused into patients in the leukapheresis product; the effect of tumor cell reinfusion has not been well studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor growth factor: May potentially act as a growth factor for any tumor type, particularly myeloid malignancies; caution should be exercised when using in any malignancy with myeloid characteristics. Discontinue use if disease progression occurs during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300028\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222861\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9878&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Sargramostim may enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Sargramostim may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220007\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220021\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16571004\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sargramostim is present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220009\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (twice weekly during treatment), renal/liver function tests (at least every 2 weeks in patients displaying renal or hepatic dysfunction prior to treatment initiation); pulmonary function; vital signs; hydration status; weight</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219999\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sargramostim stimulates proliferation, differentiation, and functional activity of neutrophils, eosinophils, monocytes, and macrophages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220017\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Increase in WBC in 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: WBCs return to baseline within 1 to 2 weeks of discontinuing drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 months to 15 years: IV: Median: 1.6 hours; range: 0.9 to 2.5 hours; SubQ: Median: 2.3 hours (0.3 to 3.8 hours) (Stute 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: IV: ~60 minutes; SubQ: ~2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: 1 to 3 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323819\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Leukine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (1): $297.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038802\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Interberin (AT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Disease Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/21205990/pubmed\" target=\"_blank\" id=\"21205990\">21205990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leukine (sargramostim) [prescribing information]. Bridgewater NJ: Sanofi-Aventis; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leukine (sargramostim) [prescribing information]. Bridgewater NJ: Sanofi-Aventis; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (1) <i>N Engl J Med</i>, 1992, 327(1):28-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/1375975/pubmed\" target=\"_blank\" id=\"1375975\">1375975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (2) <i>N Engl J Med</i>, 1992, 327(2):99-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/1376442/pubmed\" target=\"_blank\" id=\"1376442\">1376442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer D and Bednarczyk EM, &ldquo;Interaction of Colony-Stimulating Factors and Fluorodeoxyglucose F<sup>18</sup> Positron Emission Tomography,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1796-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/12398579/pubmed\" target=\"_blank\" id=\"12398579\">12398579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozer H, Armitage JO, Bennett CL, et al, &ldquo;2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. American Society of Clinical Oncology Growth Factors Expert Panel,&rdquo; <i>J Clin Oncol</i>, 2000, 18(20):3558-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/11032599/pubmed\" target=\"_blank\" id=\"11032599\">11032599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/26169616/pubmed\" target=\"_blank\" id=\"26169616\">26169616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Khatcheressian J, Lyman GH, et al, &ldquo;2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline,&rdquo; <i>J Clin Oncol</i>, 2006, 24(19):3187-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/16682719/pubmed\" target=\"_blank\" id=\"16682719\">16682719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stute N, Furman WL, Schell M, et al, &ldquo;Pharmacokinetics of Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor in Children After Intravenous and Subcutaneous Administration,&rdquo; <i>J Pharm Sci</i>, 1995, 84(7):824-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/7562431/pubmed\" target=\"_blank\" id=\"7562431\">7562431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waselenko JK, MacVittie TJ, Blakely WF, et al, &quot;Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group,&quot; <i>Ann Intern Med</i>, 2004, 140(12):1037-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/15197022/pubmed\" target=\"_blank\" id=\"15197022\">15197022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20879881\"></a>Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med.</i> 2010;363(14):1324-1334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sargramostim-drug-information/abstract-text/20879881/pubmed\" target=\"_blank\" id=\"20879881\">20879881</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9878 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220032\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220033\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F220055\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F220035\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46193210\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F220036\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22553572\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553573\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220011\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F219996\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F220015\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F220014\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25472097\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F220065\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220003\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220018\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220000\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300028\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222861\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F220007\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220021\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16571004\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F220009\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219999\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F220017\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323819\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038802\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9878|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sargramostim-patient-drug-information\" class=\"drug drug_patient\">Sargramostim: Patient drug information</a></li><li><a href=\"topic.htm?path=sargramostim-pediatric-drug-information\" class=\"drug drug_pediatric\">Sargramostim: Pediatric drug information</a></li></ul></div></div>","javascript":null}